National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 4) 2018 (Cth)

National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 4) 2018

National Health Act 1953

I, Masha Somi, delegate of the Minister for Health, make this Determination under subsection 9B(2) of the National Health Act 1953.

Dated     30 October 2018

Dr Masha Somi

Assistant Secretary

Immunisation Branch

Office of Health Protection

Chief Medical Officer Group

Department of Health

1. Name of Determination

This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination (No. 4) 2018.

1. Commencement

This Determination commences on the day after registration.

3       Authority

This Determination is made under subsection 9B(2) of the National Health Act 1953.          

1. Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)

The Schedule varies the National Health (Immunisation Program – Designated     Vaccines) Determination 2014 (No. 1).

Schedule

[1] Subsection 7(1)

Omit, substitute

(1)   For item 110 of Schedule 1, a designated vaccine in that item may be provided in the following circumstances:

(a)   a dose of the vaccine may be provided to a child:

(i) who is an Aboriginal and/or Torres Strait Islander; and

(ii) who is about 6 months; and

(iii) who lives in Queensland, Western Australia, South Australia or the Northern Territory;

[2] Item 108A in Schedule 1, Part 1

Omit, substitute

108A Vaccine Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate Circumstances Vaccine may be provided to: (a)   a child who is 12 months old; or (b)     a person who is at least 14 years old but less than 20 years of age.  Nimenrix Injection (0.5mL) After reconstitution, each of the following: (a)    Meningococcal polysaccharide - Serogroup A[1] — 5 μg (b)   Meningococcal polysaccharide - Serogroup C¹ — 5 μg (c)    Meningococcal polysaccharide - Serogroup W-135¹ — 5 μg (d)   Meningococcal polysaccharide - Serogroup Y¹ —  5 μg 1 dose

[1] conjugated to tetanus toxoid carrier protein 44 μg